enabling the classification of patient subgroups to drive effective personalized treatment strategies and personalized disease management
deciphering complex and overlapping symptoms for a more accurate diagnosis
Companion diagnostic development
applying proprietary SeroTag technology to support targeted drug development
development of two standard markers used in the diagnosis of SSc gives the Multilisa® SSc program real power to aid medical research
Improving the lives of patients is a personal matter for each and every member of our team at Protagen. You’ll see this in the passion we apply to the discovery, identification, and validation of novel biomarker panels for better diagnostic (Dx) and companion diagnostic (CDx) tests. It is demonstrated by the commitment and expertise we bring to our partnerships when working on clinical development programs. Our dedication to advancing diagnostics for personalized medicine is evident in everything we do.
We are adding a new dimension to the world of diagnostics. Our SeroTag biomarker development engine delivers unique biomarker signatures. The disease-specific signatures that we identify, often based on novel markers, are the basis for new diagnostic strategies that will improve the differentiation and stratification of patients. The result is a new medical scenario in which disease states are recognized earlier, and medical care can be more specifically and effectively provided.